[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"dementia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:dementia":30},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,258,0,25,[9,53,81,112,137,164,215,240,266,291,311,335,363,387,414,444,506,533,571,602,649,673,700,731,757],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":34,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100392965","phase-1-pet-imaging-of-cyclooxygenases-in-neurodegenerative-brain-disease-100392965",false,"NCT04396873","PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease","Phase 1 Study: PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease","* INCLUSION CRITERIA:\n\nPatients: In order to be eligible to participate in this study, patients must meet all of the following criteria:\n\n1. Aged 18 or older.\n2. Be able (or have their Legally Authorized Representative (LAR) be able) to understand the study and be willing to sign a written informed consent document.\n3. Have been diagnosed by a neurologist or psychiatrist with MCI, ALS, PD, or an adult onset neurodegenerative dementia, such as AD (including amyloid negative subjects), FTD, corticobasal syndrome, or Huntington s disease.\n4. Be in good general health as evidenced by medical history and physical examination.\n5. Have their radial artery pulse checked for the presence of adequate ulnar collateral flow and the absence of any metal or foreign objects in both wrists.\n6. Agree to adhere to the lifestyle considerations.\n\nHealthy volunteers: In order to be eligible to participate in this study, healthy volunteer subjects must meet all of the following criteria:\n\n1. Aged 18 or older.\n2. Female participants of childbearing potential must be using a medically acceptable means of contraception\n3. Able provide informed consent.\n4. Be in good general health, as evidenced by medical history and physical examination, and have no cognitive impairment.\n5. Be enrolled in 01-M-0254, The Evaluation of Participants with Mood and Anxiety Disorders and Healthy Volunteers or 17-M-0181, Recruitment and Characterization of Healthy Research Volunteers for NIMH Intramural Studies\n6. Have their radial artery pulse checked for the presence of adequate ulnar collateral flow and the absence of any metal or foreign objects in both wrists.\n7. Agree to adhere to the lifestyle considerations.\n\nEXCLUSION CRITERIA:\n\nBoth patients and healthy volunteers who meet any of the following criteria will be excluded from participation in this study:\n\n1. Clinically significant abnormalities on EKG or laboratory testing. This includes CBC and acute care panel (Na, K, Cl, CO2, creatinine, glucose, urea nitrogen). Any lab value that is two-times the upper limit or even lower values in the investigator s judgment. Creatinine level \\>1.3 mg\u002FdL\n2. Subjects should not have taken Non-Steroidal Anti-Inflammatory Drugs (NSAID) for two weeks prior to the PET scan. Aspirin, corticosteroids (with the exception of skin products), or immunosuppressants (e.g., methotrexate) must not have been taken in the prior month.\n3. Contraindications to ketoprofen, such as hypersensitivity to ketoprofen or history of upper or lower gastrointestinal bleeding.\n4. Have other major neurological or medical diseases that may cause cognitive dysfunction, such as structural brain diseases, metabolic diseases, paraneoplastic syndromes, infectious diseases, or other significant neurological abnormalities.\n5. Have an unstable medical condition that, in the opinion of the investigators, makes participation unsafe (e.g., an active infection or untreated malignancy).\n6. Are unable to travel to the NIH.\n7. Have recent exposure to radiation related to research (e.g., PET from other research) that, when combined with this study, would be above the allowable limits.\n8. Have an inability to lie flat and\u002For lie still on the camera bed for at least two hours, including claustrophobia, overweight greater than the maximum for the scanner, and uncontrollable behavioral symptoms, which will be screened by an interview with the patient and\u002For caregiver during the screening visit.\n9. Participants must not have substance use disorder or alcohol use disorder. However, alcohol or cannabis use by themselves are not exclusion criteria, unless that use impairs function of daily life.\n10. Participants should not be under treatment with Aduhelm, nor should they have been treated in the past.\n11. Are unable to have an MRI scan (e.g., because of pacemakers or other implanted electrical devices, brain stimulators, dental implants, aneurysm clips (metal clips on the wall of a large artery), metallic prostheses (including metal pins and rods, heart valves, and cochlear implants), permanent eyeliner, implanted delivery pumps, shrapnel fragments, or metal fragments in the eye).\n12. Pregnancy\n13. HIV infection\n14. Be NIMH staff or an NIH employee who is a subordinate\u002Frelative\u002Fco-worker of the investigators.",true,"ALL","18 Years","99 Years",{"count":22,"type":23},184,"ESTIMATED","INTERVENTIONAL",[26],"PHASE1","Background:\n\nAbout 5 million adults in the U.S. have Alzheimer s disease or another adult-onset neurodegenerative disorder. Many studies have found that inflammation in the brain contributes to these diseases. Researchers want to find a better way to measure this inflammation.\n\nObjective:\n\nTo learn whether COX-1 and\u002For COX-2 is elevated in the brains of individuals with neurodegenerative brain disease compared to healthy volunteers.\n\nEligibility:\n\nAdults age 18 years and older in good general health who have an adult-onset neurodegenerative dementia, such as AD, FTD, corticobasal syndrome, Huntington s disease, or MCI, ALS and healthy adult volunteers enrolled in protocols 01-M-0254 or 17-M-0181.\n\nDesign:\n\nParticipants will be screened with medical history, physical exam with vital signs, and lab tests. They will have a neuropsychological testing. Their heart function will be measured.\n\nParticipants will have a magnetic resonance imaging (MRI) scan. The MRI scanner is a metal tube surrounded by a strong magnetic field. Participants will lie on a table that slides in and out of the tube. The machine makes noise. Participants will get earplugs.\n\nParticipants will have 2 PET scans. They will be injected with the study drugs through an intravenous catheter placed in an arm vein. The PET scanner is shaped like a doughnut. Participants will lie on a bed that slides in and out of the scanner. A plastic mask will be molded to their head to keep them from moving. A thin plastic tube will be put into an artery at the wrist or elbow crease area. This will be used to draw blood during the scan.\n\nParticipants will have 2-5 study visits. Participation lasts 1 week to 4 months, depending on scheduling.",[29,30,31,32,33],"Parkinson's Disease","Dementia","Alzheimer's Disease","ALS","Mild Cognitive Impairment",[35,36,37,30,38,32,39],"PET Imaging","PD","Inflammation","Cyclooxygenase-2","MCI","RECRUITING","2026-07-01",{"date":43,"type":44},"2026-07-02","ACTUAL",{"date":46,"type":44},"2021-08-17",{"date":48,"type":23},"2030-10-03",{"name":50,"class":51},"National Institute of Mental Health (NIMH)","NIH",1,{"id":54,"slug":55,"hasResults":12,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":17,"sex":18,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":4,"studyType":24,"phases":65,"briefSummary":67,"conditions":68,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":52},"100645236","financial-counseling-for-dementia-family-caregivers-in-early-and-middle-adulthood-100645236","NCT07681401","Financial Counseling for Dementia Family Caregivers in Early and Middle Adulthood","Financial Counseling and Advocacy for Alzheimer's Disease and Related Dementias Family Caregivers in Early and Middle Adulthood","FCA 4 FC-EAMA","Inclusion Criteria:\n\n* Caring for a family member, neighbor, or friend with ADRD\n* Providing care for 20 or more hours per week,\n* Technology access for Zoom visits\n* English speaking\n\nExclusion Criteria:\n\n* N\u002FA","25 Years","55 Years",{"count":64,"type":23},10,[66],"NA","The goal of this National Institutes of Health (NIH) Stage 1a study is to develop and pilot test a research- and community-informed financial counseling and advocacy (FCA) intervention for dementia family caregivers in early and middle adulthood. The main question it aims to answer is:\n\nIs a research- and community-informed financial counseling and advocacy intervention usable, feasible and acceptable for dementia family caregivers in early and middle adulthood?\n\nParticipants will engage in a four-week single group financial counseling and advocacy intervention and complete pre- and post-intervention measures addressing financial well-being, caregiver strain, workplace productivity, and flourishing along with usability, acceptability, and feasibility measures.",[69,30,70,71],"Family Caregivers","Financial Wellbeing","Financial Coaching","2026-06-25",{"date":43,"type":44},{"date":75,"type":44},"2026-04-10",{"date":77,"type":23},"2026-10",{"name":79,"class":80},"University of Utah","OTHER",{"id":82,"slug":83,"hasResults":12,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":17,"sex":18,"minAge":88,"maxAge":4,"enrollmentInfo":89,"targetDuration":91,"studyType":92,"phases":4,"briefSummary":93,"conditions":94,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":52},"100644884","clinical-risk-score-prediction-for-risk-of-dementia-among-late-life-population-with-depression-100644884","NCT07676851","Clinical Risk Score Prediction for Risk of Dementia Among Late-life Population With Depression","Development of a Clinical Risk Score Prediction Tool for 5-, 9-, and 13-year Risk of Dementia Among Late-life Population With Depression: a Longitudinal Cohort Study","Inclusion Criteria:\n\n* Adults aged ≥50 years.\n* A diagnosis of depression clearly recorded by a clinician in the electronic medical record at baseline (based on structured or unstructured diagnostic documentation formed through routine clinical practice).\n* Complete baseline electronic medical record data available, including at least demographic information (age, sex), clinical diagnoses, comorbidities, and medication records.\n* At least one follow-up record available in the electronic medical record system to enable determination of incident dementia outcomes.\n* Informed consent provided for the use of routine medical data for this research analysis.\n\nExclusion Criteria:\n\n* Any type of dementia diagnosis recorded in the electronic medical record at baseline (including Alzheimer's disease, vascular dementia, and other types of dementia).\n* Medical record documentation indicating that the diagnosis of dementia preceded the diagnosis of depression, or an inability to clearly determine the chronological order of the two diagnoses.\n* Presence of other neurological diseases at baseline that may independently cause severe cognitive impairment (e.g., Parkinson's disease, multiple sclerosis, brain tumor, normal pressure hydrocephalus).\n* Missing key baseline electronic medical record data that would preclude subsequent risk model analysis.\n* Incomplete follow-up information or inability to clearly confirm incident dementia outcomes through the electronic medical record system.\n* Refusal to participate in the study or withdrawal of informed consent.","50 Years",{"count":90,"type":23},44,"13 Years","OBSERVATIONAL","The goal of this observational study is to learn about the ability of a point risk score prediction model, developed using electronic medical record data, to predict the risk of progression from geriatric depression to dementia in older Chinese adults. The main questions it aims to answer are:\n\nDoes a higher point risk score increase the risk of developing dementia in older adults with depression?\n\nWhat is the accuracy of the point risk score prediction model in identifying individuals at high risk of dementia among older adults with depression?\n\nParticipants will receive their usual medical care as they normally would. No new treatments, tests, or procedures will be performed specifically for this study. The research team will collect data from their electronic medical records, including depression diagnoses, dementia diagnoses, comorbidities, medication records, and follow-up information. The point risk score will be calculated based on these routinely collected clinical data.",[95,30,96,97,98,99,100,101,102],"Alzheimer Dementia (AD)","Late Life Depression (LLD)","Risk Scores","Prediction","Chinese Population","Obs e r","Observational Cohort Study","External Validation","2026-06-24",{"date":105,"type":44},"2026-06-30",{"date":107,"type":44},"2006-06-01",{"date":109,"type":23},"2030-06-30",{"name":111,"class":80},"Second Affiliated Hospital of Nanchang University",{"id":113,"slug":114,"hasResults":12,"nctId":115,"briefTitle":116,"officialTitle":116,"acronym":117,"eligibilityCriteria":118,"healthyVolunteers":12,"sex":18,"minAge":62,"maxAge":4,"enrollmentInfo":119,"targetDuration":4,"studyType":24,"phases":121,"briefSummary":122,"conditions":123,"keywords":125,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":52},"100644705","brain-wave-informed-non-invasive-brain-stimulation-improving-neural-networks-of-working-memory-in-dementia-a-proof-of-concept-study-100644705","NCT07673770","Brain Wave Informed Non-invasive Brain Stimulation: Improving Neural Networks of Working Memory in Dementia: a Proof-of-concept Study","BWIBS-WM","Inclusion Criteria:\n\n* Individuals must be diagnosed with Alzheimer's Disease or related dementias by a clinician.\n* Individuals must exhibit adequate oral communication skills and cognitive function sufficient to obtain a score above 10 on the MMSE\n* Instructions will be delivered in English; therefore participants must demonstrate an understanding of instruction provided in English.\n* Individuals must be at least 55 years or older\n\nExclusion Criteria:\n\n* Contraindications to TMS; presence of a pacemaker, metal\u002Felectrical\u002Fmagnetic implants not including titanium, known history of untreated or uncontrolled psychological disorders, pregnancy, history of seizure or diagnoses of epilepsy, are taking any prescription medications that increase the risk of seizure.\n* Allergy to rubbing alcohol, which is needed to prepare electromyography for TMS",{"count":120,"type":23},30,[66],"Working memory helps us hold information for a short time so one can think and make decisions. It keeps thoughts on track. As one gets older, working memory gets weaker. In people with dementia, it gets much worse, making it harder to talk with others, follow directions, or remember things like shopping lists.\n\nThis may happen because brain waves that support working memory fall out of sync. Researchers can see these brain waves using a test called EEG. In this study, the investigators will try to get these brain waves back in sync using a safe, non-invasive form of brain stimulation called transcranial magnetic stimulation (TMS), and will time it to each person's brain waves to make it more effective. The goal is to improve working memory in people with dementia. If successful, dementia patients may be able to be more independent taking pressure off their families.",[30,124],"Alzheimer s Disease",[30,31,126,127,128],"transcranial magnetic stimulation","eeg","electroencephalography",{"date":130,"type":44},"2026-06-29",{"date":132,"type":23},"2026-06-01",{"date":134,"type":23},"2028-08-01",{"name":136,"class":80},"McMaster University",{"id":138,"slug":139,"hasResults":12,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":4,"eligibilityCriteria":143,"healthyVolunteers":12,"sex":18,"minAge":62,"maxAge":4,"enrollmentInfo":144,"targetDuration":4,"studyType":24,"phases":146,"briefSummary":148,"conditions":149,"keywords":152,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":163},"100640230","phase-3-a-study-of-donanemab-ly3002813-in-participants-who-completed-study-aacm-trailblazer-alz-3-ext-100640230","NCT07602582","A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).","An Annual Dosing Study of Donanemab in Participants Who Completed Donanemab Study AACM","Inclusion Criteria:\n\n* Have completed study AACM Addendum 7.\n* Have a reliable study partner and backup study partner familiar with overall function and behavior, such as day-to-day activities and cognitive abilities.\n* Are individuals assigned female at birth who are not of childbearing potential, or are individuals assigned male at birth.\n* Contraceptive use by participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.\n\nExclusion Criteria:\n\n* Current serious or unstable illnesses that, in the investigator's opinion, could interfere with participation in this study.\n* Have any contraindications for magnetic resonance imaging (MRI), including claustrophobia or the presence of contraindicated metal (ferromagnetic) implants\u002Fcardiac pacemaker.\n* Have any intracranial abnormality or lesion, including but not limited to macrohemorrhage, inflammation, or structural findings that, in the opinion of the investigator, may pose an unacceptable safety risk to the participant. Screening MRI finding of amyloid-related imaging abnormalities with edema (ARIA-E) may be monitored for resolution.\n* Contraindication to florbetapir F 18 PET.\n* Have had history of amyloid-targeting therapy treatment outside donanemab trials.\n* Have participated, within the last 30 days, in a clinical trial involving a study intervention judged not to be scientifically or medically compatible with this study.",{"count":145,"type":23},550,[147],"PHASE3","The main purpose of this study is to determine if participants who previously took donanemab get clinical benefit when they receive annual doses. For each participant, the study will last up to 2.5 years and will include 6 visits.",[150,30,151],"Alzheimer Disease","Plaque, Amyloid",[153],"Donanemab",{"date":155,"type":44},"2026-06-26",{"date":157,"type":44},"2026-05-22",{"date":159,"type":23},"2029-09",{"name":161,"class":162},"Eli Lilly and Company","INDUSTRY",58,{"id":165,"slug":166,"hasResults":12,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":170,"eligibilityCriteria":171,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":172,"targetDuration":4,"studyType":24,"phases":174,"briefSummary":175,"conditions":176,"keywords":200,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":207,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":214},"100270060","neurologic-stem-cell-treatment-study-100270060","NCT02795052","Neurologic Stem Cell Treatment Study","Neurologic Bone Marrow Derived Stem Cell Treatment Study","NEST","Inclusion Criteria:\n\n1. Have documented functional damage to the central or peripheral nervous system unlikely to improve with present standard of care.\n2. Be at least 6 months post-onset of the disease.\n3. If under current medical therapy (pharmacologic or surgical treatment) for the condition be considered stable on that treatment and unlikely to have reversal of the associated neurologic functional damage as a result of the ongoing pharmacologic or surgical treatment.\n4. In the estimation of Dr. Weiss and the neurologists have the potential for improvement with BMSC treatment and be at minimal risk of any potential harm from the procedure.\n5. Be over the age of 18 and capable of providing informed consent.\n6. Be medically stable and able to be medically cleared by their primary care physician or a licensed primary care practitioner for the procedure. Medical clearance means that in the estimation of the primary care practitioner, the patient can reasonably be expected to undergo the procedure without significant medical risk to health.\n\nExclusion Criteria:\n\n1. All patients must be capable of an adequate neurologic examination and evaluation to document the pathology. This will include the ability to cooperate with the exam.\n2. Patients must be capable and willing to undergo follow up neurologic exams with the sub-investigators or their own neurologists as outlined in the protocol.\n3. Patients must be capable of providing informed consent.\n4. In the estimation of Dr. Weiss the BMSC collection and treatment will not present a significant risk of harm to the patient's general health or to their neurologic function. .\n5. Patients who are not medically stable or who may be at significant risk to their health undergoing the procedure will not be eligible.\n6. Women of childbearing age must not be pregnant at the time of treatment and should refrain from becoming pregnant for 3 months post treatment.",{"count":173,"type":23},500,[66],"This is a human clinical study involving the isolation of autologous bone marrow derived stem cells (BMSC) and transfer to the vascular system and inferior 1\u002F3 of the nasal passages in order to determine if such a treatment will provide improvement in neurologic function for patients with certain neurologic conditions. http:\u002F\u002Fmdstemcells.com\u002Fnest\u002F",[177,178,179,180,181,182,183,184,185,186,187,188,189,190,191,192,32,193,194,195,150,30,196,197,198,199],"Neurologic Disorders","Nervous System Diseases","Neurodegenerative Diseases","Neurological Disorders","Stroke","Traumatic Brain Injury","Cadasil","Chronic Traumatic Encephalopathy","Cerebral Infarction","Cerebral Ischemia","Cerebral Stroke","Cerebral Hemorrhage","Parkinson","Multi-System Degeneration","MSA - Multiple System Atrophy","Progressive Supranuclear Palsy","Amyotrophic Lateral Sclerosis","Neuropathy","Diabetic Neuropathies","Frontotemporal Dementia","Lewy Body Disease","Cognitive Impairment","Lewy Body Variant of Alzheimer Disease",[201,202,181,182,203,204,194,205,186,198,30,206],"Neurologic Disease","Cerebral Vascular Accident","Multiple Sclerosis","Parkinsons Disease","Diabetic Neuropathy","Neurodegeneration",{"date":155,"type":44},{"date":209,"type":44},"2016-06",{"date":211,"type":23},"2028-07-31",{"name":213,"class":162},"MD Stem Cells",3,{"id":216,"slug":217,"hasResults":12,"nctId":218,"briefTitle":219,"officialTitle":220,"acronym":4,"eligibilityCriteria":221,"healthyVolunteers":12,"sex":18,"minAge":222,"maxAge":223,"enrollmentInfo":224,"targetDuration":4,"studyType":24,"phases":226,"briefSummary":227,"conditions":228,"keywords":229,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":233,"startDateStruct":234,"completionDateStruct":236,"leadSponsor":238,"locationsCount":52},"100644642","far-infrared-therapy-for-the-effect-of-alzheimer-disease-dementia-100644642","NCT07672171","Far-Infrared Therapy for the Effect of Alzheimer Disease Dementia","To Explore the Effect of Far Infrared Therapy on Cognitive Function of Patients With Dementia","Inclusion Criteria:\n\n1. Diagnosed with Alzheimer's disease dementia.\n2. Mini-Mental State Examination (MMSE) score between 18 and 24 (inclusive).\n3. Currently prescribed and maintained on a stable regimen of anti-dementia medication.\n4. No sensory deficits or impairment regarding skin temperature perception.\n5. Patient or a Legally Authorized Representative (LAR) must be willing and capable of providing written informed consent prior to enrollment.\n\nExclusion Criteria:\n\n1. Non-Alzheimer's disease dementia (e.g., vascular dementia, Lewy body dementia, frontotemporal dementia).\n2. Known hypersensitivity to heat or light, including the current use of photosensitizing medications.\n3. Diminished thermal or heat sensitivity, such as from the concurrent use of analgesics, sedatives, or consumption of alcoholic beverages.\n4. Acute injury or acute localized inflammation, including active inflammation, infection, or ulcerated wounds.\n5. Concomitant acute venous thrombosis, varicose veins, severe peripheral arterial occlusive disease (Stage III or IV), lymphatic disease, acute rheumatoid arthritis, acute gout, or active fever.\n6. Presence of mottled erythema or other abnormal dermatological conditions on the scalp or neck.\n7. Localized skin lesions, damage, or open wounds at the device contact sites.\n8. Concurrent participation in any other clinical trial.\n9. Any other underlying pathological conditions or clinical statuses that, based on medical consensus, would preclude safe participation in the study.\n10. Failure or refusal to provide signed informed consent.\n11. Inability or unwillingness to comply with the trial protocols, schedules, or required follow-up evaluations.\n12. History or presence of hemorrhagic disorders or bleeding-related diseases.","61 Years","92 Years",{"count":225,"type":23},40,[66],"Alzheimer's disease (AD), the most common cause of dementia, is a progressive neurodegenerative disorder characterized by cognitive decline, including impaired learning ability, memory loss, and behavioral disturbances.\n\nAccording to surveys conducted by the Ministry of Health and Welfare in Taiwan, the prevalence of dementia among individuals aged 65 years and older was estimated at 7.86% in 2018, affecting more than 280,000 individuals, and is projected to approach 900,000 by 2065, resulting in substantial medical, social, and economic burdens. Current pharmacological treatments provide only limited symptomatic benefits and may be associated with adverse effects. Therefore, safe and effective non-pharmacological interventions that may support cognitive function and reduce caregiver burden are urgently needed.\n\nExperimental studies suggest that far-infrared (FIR) irradiation may enhance mitochondrial oxidative phosphorylation, increase ATP production, and promote microglial amyloid-β clearance, which may help delay the progression of Alzheimer's disease.\n\nThis trial aims to investigate the safety and effects of far-infrared (FIR) therapy on cognitive function in patients with Alzheimer's disease.\n\nThe findings may support the clinical application of FIR therapy as a non-pharmacological intervention to improve cognitive function and quality of life, reduce medication burden and treatment-related side effects, lessen caregiver burden, delay institutionalization, and reduce the social and economic burden associated with Alzheimer's disease.",[30,150],[230,30,231],"Far-infrared therapy","Alzheimer disease","2026-06-23",{"date":155,"type":44},{"date":235,"type":44},"2022-10-15",{"date":237,"type":23},"2029-10-31",{"name":239,"class":80},"Juin-Hong Cherng",{"id":241,"slug":242,"hasResults":12,"nctId":243,"briefTitle":244,"officialTitle":244,"acronym":4,"eligibilityCriteria":245,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":246,"targetDuration":4,"studyType":24,"phases":248,"briefSummary":249,"conditions":250,"keywords":252,"overallStatus":258,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":259,"startDateStruct":260,"completionDateStruct":262,"leadSponsor":264,"locationsCount":52},"100519625","automated-assistive-non-contact-sleep-quality-monitor-for-individuals-with-alzheimers-disease-100519625","NCT06045988","Automated, Assistive, Non-Contact Sleep Quality Monitor for Individuals With Alzheimer's Disease","Inclusion Criteria:\n\n* Diagnosis of Alzheimer's Disease (AD) or Alzheimer's Disease Related Dementias (ADRD)\n* Residents of long-term care (LTC) facility study site location for a minimum of 30 days.\n* Willingness to consent to study or when a potential participant lacks decision making capacity (determined by LTC facility clinical provider) willingness of a Legally Authorized Representative (LAR) to consent to study participation on potential participant's behalf.\n\nExclusion Criteria:\n\n* Currently on hospice",{"count":247,"type":23},100,[66],"This study seeks to evaluate the utility and efficacy of the Non-Contact Sleep Quality Monitor System when used to monitor the sleep quality of individuals living in long-term care (LTC) with either Alzheimer's Disease (AD) or Alzheimer's Disease Related Dementia (ADRD). This before-after comparison trial will be conducted in several LTC facilities to evaluate the effect access to System Sleep Quality Data has on documentation of sleep disorders or treatments and sleep quality change over time for AD\u002FADRD participants in the intervention group as compared to the control group.\n\nAll subjects will undergo sleep quality monitoring for 4-weeks. At the end of the first 2-weeks, research staff and LTC facility staff and medical providers will receive access to sleep monitoring data. We hypothesize that when real-time System Sleep Data is shared with LTC staff or healthcare providers, that sleep disturbances will be more readily detected, leading to timelier, better tailored treatment interventions for sleep disturbances, thereby improving sleep quality and decreasing daytime physical inactivity.",[150,30,251],"Sleep Disturbance",[253,254,255,30,256,257],"Sleep Assessment","Sleep Disorder","Technology","Long-Term Care","Sleep Monitoring","NOT_YET_RECRUITING",{"date":155,"type":44},{"date":261,"type":23},"2026-07",{"date":263,"type":23},"2026-12",{"name":265,"class":80},"Indiana University",{"id":267,"slug":268,"hasResults":12,"nctId":269,"briefTitle":270,"officialTitle":270,"acronym":4,"eligibilityCriteria":271,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":272,"enrollmentInfo":273,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":275,"conditions":276,"keywords":278,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":284,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":289,"locationsCount":52},"100210276","genetic-characterization-of-movement-disorders-and-dementias-100210276","NCT02014246","Genetic Characterization of Movement Disorders and Dementias","* INCLUSION CRITERIA\n\nFor Patients:\n\n* Diagnosis of a movement disorder or dementia by a neurologist or other qualified professional and accompanied by sufficient clinical and\u002For laboratory evidence to support the diagnosis\n* Confirmation of a movement disorder or dementia by study investigators or a qualified clinician by physical examination and\u002For review of medical records\n* Ages 18 and above\n* Able to provide consent or, in the case of minors, or cognitive impairment, have a legally-authorized representative to provide consent\n* Able to understand and participate in study procedures or for those without consent capacity, able to participate in study procedures AND has a legally authorized representative that understands the study procedures and can consent on their behalf.\n\nFor unaffected family members of patients:\n\n* Unaffected relative of a patient diagnosed with a movement disorder or dementia enrolled in this protocol. For these purposes, we define a family member as an individual for which there is a demonstrable relationship with the proband in the pedigree. This is a standard approach used in family-based studies. Furthermore, the related patient (defined as a family member diagnosed with the disease of interest) must be enrolled in the study.\n* Ages 18 and above\n* Able to provide consent\n* Able to understand and participate in study procedures\n\nFor unrelated healthy control individuals:\n\n* Be in good general health\n* Have no known movement disorder or dementia, or family member with a movement disorder or dementia\n* Age 18 and above\n* Able to provide consent\n* Able to understand and participate in study procedures\n\nEXCLUSION CRITERIA\n\nFor patients:\n\n-An identifiable, non-genetic etiology for the movement disorder or dementia, such as a specific environmental exposure, birth injury, metabolic disorder, or brain infection such as encephalitis\n\nFor all participants:\n\n* Clinically significant anemia that would make phlebotomy unsafe, and participant unwilling to provide saliva sample.\n* Clinically significant bleeding that would make phlebotomy unsafe, and participant unwilling to provide saliva sample.\n* Any medical condition that would make phlebotomy unsafe or undesirable, such as a serious medical illness like unstable heart disease, or unstable chronic obstructive pulmonary disease, and participant unwilling to provide saliva sample.","120 Years",{"count":274,"type":23},12000,"Background:\n\nThere are two basic types of movement disorders. Some cause excessive movement, some cause slowness or lack of movement. Some of these are caused by mutations in genes. On the other hand, dementia is a condition of declining mental abilities, especially memory. Dementia can occur at any age but becomes more frequent with age. Researchers want to study the genes of families with a history of movement disorders or dementia. They hope to find a genetic cause of these disorders. This can help them better understand and treat the diseases. This study will not be limited to a particular disorder, but will study all movement disorders or dementias in general. This study will perform genetic testing to identify the genetic causes of movement disorders and dementia. Today, genetic testing can be done to analyze multiple genes at the same time. This increases the chances of finding the genetic cause of movement disorders and dementias.\n\nObjectives:\n\nTo learn more about movement disorders and dementia, their causes, and treatments.\n\nEligibility:\n\nAdults and children with a movement disorder or dementia, and their family members.\n\nHealthy volunteers.\n\nDesign:\n\nParticipants will be screened with medical history and blood tests. Some will have physical exam.\n\nParticipants will give a blood sample by a needle in the arm. This can be done at the clinic, by their own doctor, or at home. Alternatively, a saliva sample may be provided if a blood sample cannot be obtained.\n\nParticipants can opt to send an extra blood sample to a repository for future study. Genetic test will be done on these samples. The samples will be coded. The key to the code will remain at NIA. Only NIA investigators will have access to the code key. Participants can request to receive results of the tests.\n\nParticipation is generally a single visit. Participants may be called back for extra\n\n...",[30,277],"Movement Disorder",[279,280,281,282,283],"Movement Disorders","Polymorphisms","DNA","Lymphoblastoid Cell Lines","Natural History",{"date":103,"type":44},{"date":286,"type":44},"2003-07-14",{"date":288,"type":4},"2059-12-31",{"name":290,"class":51},"National Institute on Aging (NIA)",{"id":292,"slug":293,"hasResults":12,"nctId":294,"briefTitle":295,"officialTitle":295,"acronym":296,"eligibilityCriteria":297,"healthyVolunteers":17,"sex":18,"minAge":88,"maxAge":298,"enrollmentInfo":299,"targetDuration":4,"studyType":24,"phases":300,"briefSummary":301,"conditions":302,"keywords":4,"overallStatus":258,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":305,"startDateStruct":307,"completionDateStruct":308,"leadSponsor":309,"locationsCount":4},"100641282","cooking-health-oriented-meals-to-prevent-dementia-and-diabetes-100641282","NCT07661368","Cooking Health-Oriented Meals to Prevent Dementia and Diabetes","CHOMPDD","Inclusion Criteria:\n\n* Age: 50 - 75 yrs\n* Score of 5 or greater on ADA (diabetes) screener\n* Self-report family history of dementia or AD\n* Smartphone (iOS or Android)\n* Verbal and written informed consent\n\nExclusion Criteria:\n\n* Food allergies or conditions requiring a specialized diet that would limit participation","75 Years",{"count":225,"type":23},[66],"Previous research demonstrates that 1) adherence to a DASH dietary pattern and diets low in certain UPFs are linked to lower likelihood of experiencing cognitive impairments in later life (Seago et al., 2025a, 2025b), that 2) engagement in cooking is linked to healthier eating, reduced UPF consumption, and higher food self-efficacy (Lahne et al., 2017), and 3) that cooking activity itself in midlife is associated with reduced incidence of dementia (Tani et al., 2026). There may be multiple pathways through which cooking engagement facilitates healthier cognitive aging- including the benefits of healthier meals on cardiometabolic and neural health, but also the role of cooking as a cognitively-engaging activity - one that has been identified as a potential contributor to cognitive reserve during aging. While at least one computerized cognitive training program is based on cooking activities and has demonstrated improvements to untrained EF processes in older adults, no intervention has used actual cooking as a form of cognitive training. Part of the promise of such an intervention is that this sort of activity, while still engaging EF processes in a way that might lead to generalizable improvements, is much closer to real-world instrumental activities of daily living and may reinforce consumption of a brain- and cardiometabolic- health promoting dietary pattern. This pilot study involves a randomized controlled trial of a behavioral change intervention to promote a healthy diet by increasing cooking self-efficacy (agency), and for this study, cooking self-efficacy is the primary focus.",[303,30],"Type 2 Diabetes","2026-06-16",{"date":306,"type":44},"2026-06-22",{"date":261,"type":23},{"date":263,"type":23},{"name":310,"class":80},"Virginia Polytechnic Institute and State University",{"id":312,"slug":313,"hasResults":12,"nctId":314,"briefTitle":315,"officialTitle":315,"acronym":316,"eligibilityCriteria":317,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":318,"targetDuration":4,"studyType":24,"phases":320,"briefSummary":321,"conditions":322,"keywords":4,"overallStatus":258,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":326,"startDateStruct":328,"completionDateStruct":330,"leadSponsor":332,"locationsCount":52},"100590173","using-community-health-workers-to-support-rural-care-partners-of-seriously-ill-older-veterans-100590173","NCT06963970","Using Community Health Workers to Support Rural Care Partners of Seriously Ill Older Veterans","PATH","Inclusion Criteria:\n\nCare Partner Inclusion Criteria\n\n* A relative, friend, or partner (18 years of age) with whom Veteran patient has a personal relationship who assists Veteran regularly with care and\u002For care coordination as defined under \"Veterans\" below\n* Residing in a rural area based on RUCC or Rural-Urban Continuum Codes83\n* Must be enrolled in CSP Program of General Caregiver Support Services\n* Can live with or separately from the Veteran; able to communicate in English by phone\n\nVeteran Inclusion Criteria\n\n* Receiving care at Durham, Asheville, and Richmond VA Health Systems (e.g., at least 2 outpatient visits in past year; has a primary provider) and residing in a rural area.\n* Diagnosed with congestive heart failure, chronic obstructive pulmonary disease, cancer, dementia, or end-stage renal disease.\n* Requires assistance with at least one ADL (i.e., walking, feeding, toileting, transferring, bathing, or dressing) or IADL (i.e., transport, medication, financial management, shopping, or meal preparation)\n* 50 years old or older and able to communicate in English by phone (for assessments)\n\nExclusion Criteria:\n\nVeteran Exclusion Criteria\n\n* Flag or social work note indicating suspected Caregiver abuse.\n* Unable to communicate in English by phone for assessments.",{"count":319,"type":23},480,[66],"The investigators aim to support care partner's well-being and satisfaction with VA care and decrease their work burden by offering extra support from a trained Community Health Worker who will help connect the care partner to helpful resources in their communities and in the VA. The investigators also hope to help Veterans well-being and satisfaction with VA care by supporting their care partner more sufficiently allowing the care partner to focus on caregiving tasks.",[30,323,324,325],"Cancer","Renal Disease","Obstructive Pulmonary Disease",{"date":327,"type":44},"2026-06-17",{"date":329,"type":23},"2026-09-01",{"date":331,"type":23},"2028-09-30",{"name":333,"class":334},"VA Office of Research and Development","FED",{"id":336,"slug":337,"hasResults":12,"nctId":338,"briefTitle":339,"officialTitle":339,"acronym":340,"eligibilityCriteria":341,"healthyVolunteers":17,"sex":18,"minAge":342,"maxAge":4,"enrollmentInfo":343,"targetDuration":4,"studyType":24,"phases":344,"briefSummary":345,"conditions":346,"keywords":349,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":355,"lastUpdatePostDateStruct":356,"startDateStruct":357,"completionDateStruct":359,"leadSponsor":361,"locationsCount":52},"100627914","e-align-a-patient-portal-based-intervention-to-align-medications-with-what-matters-most-100627914","NCT07454824","e-ALIGN: A Patient Portal-based Intervention to Align Medications With What Matters Most","e-ALIGN","Inclusion Criteria:\n\n* Patients: Age ≥65, with a diagnosis of MCI or dementia based on ICD-10 codes and ≥1 active CNS-PIM, who are active patient portal users.\n\nCare partners:\n\n* Family or other companions \\>21 years who regularly help the patient with managing medications.\n\nExclusion Criteria:\n\n* As the trial will be based in primary care, individuals residing in long term care facilities or enrolled in hospice will be excluded.","65 Years",{"count":247,"type":23},[66],"The overarching goal of this study is to pilot an intervention in which older adults with mild cognitive impairment and dementia and the older adult's care partners are identified in primary care and provided with educational materials through the patient portal to engage the participant in deprescribing. The multicomponent intervention, e-Align, includes delivery of educational information through the patient portal, and a pharmacist-led intervention to align medications with patient and care partner goals and reduce use of central nervous system (CNS) potentially inappropriate medicines (PIM). This work will establish the preliminary data, methods, and partnerships to undertake a multisite embedded pragmatic clinical trial. The resulting triadic-based behavioral intervention will promote patient and care partner engagement, and foster care that aligns with patients' values, and promote improved health and well-being outcomes for people with cognitive impairment and the patient's care partners through deprescribing.",[30,347,348],"Potentially Inappropriate Medication Use","Mild Cognitive Impairment (MCI)",[350,351,352,353,354],"deprescribing","polypharmacy","potentially inappropriate medications","dementia","cognitive impairment","2026-06-15",{"date":304,"type":44},{"date":358,"type":44},"2026-04-15",{"date":360,"type":23},"2027-02-06",{"name":362,"class":80},"Johns Hopkins University",{"id":364,"slug":365,"hasResults":12,"nctId":366,"briefTitle":367,"officialTitle":368,"acronym":369,"eligibilityCriteria":370,"healthyVolunteers":12,"sex":18,"minAge":371,"maxAge":4,"enrollmentInfo":372,"targetDuration":4,"studyType":24,"phases":374,"briefSummary":375,"conditions":376,"keywords":4,"overallStatus":258,"whyStopped":4,"lastUpdateSubmitDate":380,"lastUpdatePostDateStruct":381,"startDateStruct":382,"completionDateStruct":383,"leadSponsor":385,"locationsCount":52},"100628402","penn-state-emergency-medicine-cares-care-partner-evaluation-and-sourcing-in-the-emergency-department-100628402","NCT07461168","Penn State Emergency Medicine CarES: Care-partner Evaluation and Sourcing in the Emergency Department","Penn State Emergency Medicine CarES: Care-partner Evaluation and Sourcing in the ED","CarES","Inclusion Criteria:\n\n* Person completed the CarES Observational Study.\n* Person is a care partner and:\n* Lives with the person living with dementia or\n* Checks on them at least once per week in person or by phone\n* Person is willing and able to participate in study assessments\n\nExclusion Criteria:\n\n* Person is no longer a care partner for a person living with dementia\n* Person declines participation","60 Years",{"count":373,"type":23},20,[66],"Care partners of people living with dementia often experience ongoing stress and unmet support needs. This study evaluates the feasibility of a low-intensity, supportive education and resource intervention for care partners who previously participated in an observational study.\n\nParticipants complete a baseline phone interview and a short stress journaling activity, followed by a six-week series of automated educational and supportive messages delivered by text message or email. Participants may also take part in an optional peer support focus group. The study examines caregiver stress, resilience, engagement with resources, and participant feedback to inform future caregiver support interventions.",[30,377,378,379],"Caregiver Stress","Caregiver Burden","Caregiver Burden of People With Dementia","2026-06-12",{"date":355,"type":44},{"date":41,"type":23},{"date":384,"type":23},"2026-12-30",{"name":386,"class":80},"Milton S. Hershey Medical Center",{"id":388,"slug":389,"hasResults":12,"nctId":390,"briefTitle":391,"officialTitle":391,"acronym":392,"eligibilityCriteria":393,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":394,"targetDuration":4,"studyType":24,"phases":396,"briefSummary":397,"conditions":398,"keywords":400,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":406,"lastUpdatePostDateStruct":407,"startDateStruct":408,"completionDateStruct":410,"leadSponsor":412,"locationsCount":52},"100411062","web-based-cognitive-behavioral-treatment-for-insomnia-in-dementia-caregivers-100411062","NCT04632628","Web-based Cognitive Behavioral Treatment for Insomnia in Dementia Caregivers","NiteCAPP","CAREGIVER\n\nInclusion Criteria:\n\n* 18+ yrs\n* Dementia caregiver living with person with dementia\n* willing to be randomized, 4. read\u002Funderstand English\n* insomnia diagnosis\n* no prescribed or over-the-counter sleep meds or stabilized 6+ weeks.\n\nInsomnia:\n\n* complaints for 6+ mos\n* adequate opportunity and circumstances for sleep\n* 1+ of the following: difficulty falling asleep, staying asleep, or waking too early\n* daytime dysfunction (mood, cognitive, social, occupational) due to insomnia\n* Screening interview indicates Insomnia Severity Index score ≥11 or Insomnia Severity Index score 9-10\n* baseline diaries indicate \\>30 mins of sleep onset latency or wake after sleep onset on 3+ nts.\n\nExclusion Criteria:\n\n* unable to consent\n* cognitive impairment \\[Telephone Interview for Cognitive Status (TICS) \\\u003C25 or Mini Mental State Examination (MMSE) \\\u003C26\\]\n* sleep disorder other than insomnia \\[i.e., sleep apnea (apnea\u002Fhypopnea index, AHI \\>15)\\]\n* bipolar or seizure disorder\n* other major psychopathology except depression or anxiety (e.g., suicidal ideation\u002Fintent, psychosis)\n* severe untreated psychiatric comorbidity\n* psychotropic or other medications (e.g., beta-blockers) that alter sleep\n* non-pharmacological tx for sleep or mood outside current trial.\n\nPERSONS WITH DEMENTIA\n\nInclusion Criteria:\n\n* 18+ yrs\n* Persons with dementia living with caregiver\n* Have an eligible caregiver\n* willing to be randomized\n\nExclusion Criteria:\n\n• Person with dementia or legally authorized representative is unable to consent",{"count":395,"type":23},60,[66],"Over the next 30 years, more than 10 million persons living with dementia in the United States will receive care at home from an unpaid and untrained family caregiver. At home care is preferred by caregivers and persons with dementia alike, but increases the caregiver's risk of insomnia and related negative health outcomes, including depression, anxiety, cognitive disturbances and poor quality of life. Cognitive behavioral therapy for insomnia (CBT-I) is a highly effective and established evidence based treatment for adults of all ages. Although relatively understudied in dementia caregivers, the research by our group and others suggests CBT-I is also efficacious in caregivers. Our team developed a brief (4 session) CBT-I protocol specifically adapted for dementia caregivers (CBT-I) and has shown in person and remote (i.e. telehealth) delivery of this protocol significantly reduces insomnia symptoms and improves mood (moderate to large effects). Given demands on caregivers' time and limited availability of trained CBT-I providers, a web-based version of CBT-I (WebCBT-I; the online treatment will be called NiteCAPP) is needed to increase the accessibility of this efficacious treatment. WebCBT-I will allow for flexible at home scheduling, and the skills needed to monitor caregiver treatment progress can be quickly and efficiently taught to healthcare providers. The overarching goal of this project is to develop and test WebCBT-I in caregivers of persons with dementia.\n\nObjectives\n\n1. To examine the clinical and health characteristics, including sleep, pain, fatigue, cognitive abilities, and cardiovascular health in dementia caregivers with insomnia.\n2. To examine changes in the primary clinical outcomes, including complaints of poor sleep, and fatigue.\n3. To examine changes in the secondary clinical outcomes, including mood, daytime functioning, cognitive functioning, and cardiovascular health.\n4. To examine the mechanistic variables, including arousal (heart rate variability, HRV).",[399,30],"Insomnia Chronic",[401,402,403,404,405,30],"Dementia Caregiver","Sleep","Behavioral Interventions","Online Behavioral Intervention","Insomnia","2026-06-11",{"date":355,"type":44},{"date":409,"type":44},"2023-11-14",{"date":411,"type":23},"2027-09-30",{"name":413,"class":80},"University of South Florida",{"id":415,"slug":416,"hasResults":12,"nctId":417,"briefTitle":418,"officialTitle":419,"acronym":420,"eligibilityCriteria":421,"healthyVolunteers":12,"sex":18,"minAge":88,"maxAge":422,"enrollmentInfo":423,"targetDuration":4,"studyType":24,"phases":424,"briefSummary":425,"conditions":426,"keywords":429,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":436,"lastUpdatePostDateStruct":437,"startDateStruct":438,"completionDateStruct":440,"leadSponsor":442,"locationsCount":52},"100642408","music-for-pain-and-dementia-100642408","NCT07602283","Music for Pain and Dementia","Neurophysiological and Neuroendocrinal Benefits of Music Based Interventions for Early Alzheimer's Patients and Their Caregivers","Music4Pain","Inclusion Criteria:\n\n* Clinical Dementia Rating 0.5 - 2\n* Be a person with or caregiver to a person with a diagnosis of early Alzheimer's Disease, mild dementia, and\u002For mild cognitive impairment (MCI) and chronic pain defined as non-cancer pain lasting \\>3 months that occurs most days and limits life or work activities OR Be a caregiver to a person with a diagnosis of early Alzheimer's Disease, mild dementia, and\u002For mild cognitive impairment (MCI) and chronic pain defined as non-cancer pain lasting \\>3 months that occurs most days and limits life or work activities\n* Able to provide informed consent\n* Willing to wear an EEG headset and heart rate monitoring devices\n* Willing to answer survey questions about topics related to the study\n* Willing to be audio \u002F video recorded\n* Willing to undergo QST, blood draw, heart rate data collection and cognitive testing\n\nExclusion Criteria:\n\n* Clinical Dementia Rating \\\u003C0.5 or \\> 2\n* Unable to provide informed consent\n* Endorsing suicidal ideation (SI), self-injurious behavior, or homicidal ideation (HI) above the threshold defined in the \"Risk Reduction and Safety Plan\"\n* Participating in another clinical trial studying AD and\u002For Dementia\n* Starting a new prescription medication in the last 4 weeks\n* Taking central nervous system acting medications that may interfere with study measurements as determined at PI discretion","80 Years",{"count":395,"type":23},[66],"This study aims to provide mechanistic insights into how group drumming as a music-based intervention (MBI) affects pain responses and nociceptive function in individuals with Alzheimer's Disease (AD), mild dementia or mild cognitive impairment (MCI). Heart rate (HR), heart rate variability (HRV), and brain activity will be measured during communal drumming with their dyadic partners and others. Brain activity, blood pressure, cognitive abilities, blood hormone levels, and static and dynamic pain will also be measured during sessions pre and post the 8-week community drum circle. Investigators will leverage various measurement techniques including, but not limited to, electroencephalography (EEG), quantitative sensory testing (QST), behavioral, surveys, and physiological monitoring to study the impact of group drumming on pain and brain activity in AD and inter-dyad synchrony.",[150,30,33,427,428],"Peer-bonded Caregiver","Caregiver",[430,431,432,433,434,435],"Live Music","EEG","EKG\u002FECG","Anxiety","Connectedness","Social Connection","2026-06-10",{"date":380,"type":44},{"date":439,"type":44},"2026-06-09",{"date":441,"type":23},"2028-02-01",{"name":443,"class":80},"Yale University",{"id":445,"slug":446,"hasResults":12,"nctId":447,"briefTitle":448,"officialTitle":449,"acronym":450,"eligibilityCriteria":451,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":452,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":454,"conditions":455,"keywords":474,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":439,"lastUpdatePostDateStruct":499,"startDateStruct":500,"completionDateStruct":502,"leadSponsor":504,"locationsCount":52},"100641995","human-observatory-study-100641995","NCT07646782","Human Observatory Study","The Human Observatory: A Prospective Individual and Population-Level Study of Aging, Health, and Longevity","HOS","Inclusion Criteria:\n\n* Enrolled in the 100-Year Human Aging Study at any fixed or mobile clinical site; OR completion of online health screener with provision of geographic anchor data and consent.\n\nExclusion Criteria:\n\n* Age under 18 years (current protocol; pediatric amendment planned).",{"count":453,"type":23},1000000,"The Human Observatory Study is a prospective observational and ecological surveillance study building a continuously-updating world model for human health, disease, and death at the individual and population level. Individual multi-system clinical data from enrolled participants are linked to a continuously-ingested ecological data infrastructure spanning environmental exposures, social determinants, genealogical and family history records, mortality data, and population health databases at geographic resolutions from home address to global scale and beyond. The resulting model generates individual screening recommendations informed by population-level causal estimates, and population-level causal forecasts anchored by present-timepoint individual clinical biology. Thus creating a feedback architecture designed to improve both simultaneously.",[456,457,458,459,460,461,462,463,464,465,466,30,467,468,469,470,471,472,473],"Aging","Mortality","All-cause Mortality","Life Expectancy","Cardiovascular Diseases","Neoplasms","Cognitive Dysfunction","Metabolic Syndrome","Frailty","Musculoskeletal Disease","Neurodegenerative Disease","Activities of Daily Living","Health Related Quality of Life","Disability Physical","Environmental Exposure","Occupational Diseases","Health Equity","Social Determinants of Health",[475,476,477,478,479,480,481,482,483,484,485,486,487,472,488,489,490,491,492,493,494,495,496,497,498],"longevity","biological aging","causal inference","life expectancy","exposome","Environmental Health","Social Determinants","Genealogy","Family History","Human Family Tree","Population Health","Neighborhood Health","Geographic Health Disparities","Mortality Prediction","Biomarker Validation","Cardiopulmonary Exercise Testing","Body Composition","Preventive Medicine","Healthspan","Functional Decline","Centenarian","Space Medicine","Aerospace Medicine","World Model",{"date":355,"type":44},{"date":501,"type":44},"2026-04-25",{"date":503,"type":23},"2099-12-31",{"name":505,"class":162},"Longevity Metrics, Inc.",{"id":507,"slug":508,"hasResults":12,"nctId":509,"briefTitle":510,"officialTitle":511,"acronym":4,"eligibilityCriteria":512,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":513,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":514,"conditions":515,"keywords":521,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":439,"lastUpdatePostDateStruct":528,"startDateStruct":529,"completionDateStruct":531,"leadSponsor":532,"locationsCount":52},"100636291","100-year-human-aging-study-100636291","NCT07563777","100-Year Human Aging Study","100-Year Human Aging Study: Prospective Longitudinal Validation of Multi-System Health Measurements Against Mortality and Aging Outcomes","Inclusion Criteria:\n\n* Age 18 years or older\n* Willing and able to provide written informed consent, or enrollment with consent of a legally authorized representative\n* Willing to participate in longitudinal follow-up\n\nExclusion Criteria:\n\n* Age under 18 years",{"count":453,"type":23},"The 100-Year Human Aging Study is a prospective, pragmatic, observational trial enrolling participants across fixed and mobile clinical sites to undergo comprehensive multi-system health screening and longitudinal follow-up until death. Participants are followed to determine whether measurements taken at enrollment and repeated across the lifespan - individually and in combination - predict all-cause mortality, cause-specific mortality, incident serious disease, and functional disability. The study is designed to generate the surrogate endpoint validation data that longevity medicine currently lacks.",[456,516,517,457,463,460,462,518,461,464,467,519,469,520,30],"Aging Well","All-Cause Mortality","Musculoskeletal Diseases","Health-Related Quality of Life","Neuro-Degenerative Disease",[522,490,491,492,523,488,494,493,459,524,525,526,489,527,485,495],"Longevity","Surrogate Endpoint Validation","Biological Aging","Preventive Screening","Longitudinal Cohort","Human Performance",{"date":406,"type":44},{"date":530,"type":44},"2025-02-09",{"date":503,"type":23},{"name":505,"class":162},{"id":534,"slug":535,"hasResults":12,"nctId":536,"briefTitle":537,"officialTitle":538,"acronym":4,"eligibilityCriteria":539,"healthyVolunteers":17,"sex":18,"minAge":342,"maxAge":4,"enrollmentInfo":540,"targetDuration":542,"studyType":92,"phases":4,"briefSummary":543,"conditions":544,"keywords":549,"overallStatus":258,"whyStopped":4,"lastUpdateSubmitDate":439,"lastUpdatePostDateStruct":563,"startDateStruct":564,"completionDateStruct":566,"leadSponsor":568,"locationsCount":570},"100633930","italian-validation-of-the-dna-scale-and-its-correlation-with-neurocognitive-variables-100633930","NCT07533084","Italian Validation of the dNA Scale and Its Correlation With Neurocognitive Variables","Italian Validation of the Dynamic Neurocognitive Adaptation (dNA) Scale and Its Correlation With Neurocognitive Variables","Inclusion Criteria (Stage #1):\n\n* Individuals aged ≥ 65 years residing in Italy;\n* Cognitively healthy individuals (HC);\n* Individuals with subjective memory complaints (SMC);\n* Individuals with mild cognitive impairment (MCI);\n* Individuals with probable Alzheimer's disease (AD).\n\nInclusion criteria (Stage #2 \\& Stage #3):\n\n* Individuals aged ≥ 65 years residing in Italy;\n* Cognitively healthy individuals (HC);\n* Individuals with subjective memory complaints (SMC);\n* Individuals with mild cognitive impairment (MCI);\n* Individuals with probable Alzheimer's disease (AD);\n* Individuals with Alzheimer's disease or other forms of dementia;\n* Individuals suffering from mental disorders clinically diagnosed.\n\nCognitively healthy individuals (HC):\n\n* MMSE score ≥24, or alternatively MoCA score ≥26;\n* No diagnosis of depression, MCI or any form of dementia;\n* Episodic memory performance within the normal range (Wechsler Memory Scale Logical Memory II ≥9 for 16 years of schooling or more; ≥5 for 8-15 years of schooling, ≥3 for 0-7 years of schooling; or alternatively for Prose Memory Test with scores ≥9 for ≥16 years of schooling → ≥5 items in immediate or delayed recall; ≥5 for 8-15 years of schooling → ≥3-4 items in immediate or delayed recall; ≥3 for 0-7 years of schooling → ≥2 items in immediate or delayed recall)\n\nIndividuals with Subjective Memory Complaints (SMC):\n\n* MMSE score ≥24, or alternatively MoCA score ≥26;\n* A significant memory impairment, reported by the subject, a family member, or the clinician;\n* No diagnosis of depression, MCI or any form of dementia;\n* Episodic memory performance within the normal range on the Wechsler Memory Scale Logical Memory II adjusted for years of schooling (≥9 for 16+ years of schooling, ≥5 for 8-15 years of schooling, ≥3 for 0-7 years of schooling) or, alternatively, on the Prose Memory Test (with scores ≥9 for ≥16 years of schooling → ≥5 items in immediate or delayed recall; ≥5 for 8-15 years of schooling → ≥3-4 items in immediate or delayed recall; ≥3 for 0-7 years of schooling → ≥2 items in immediate or delayed recall)\n\nIndividuals with Mild Cognitive Impairment (MCI):\n\n* MMSE score between 19 and 23 inclusive (alternatively MoCA);\n* A decline in memory reported by the subject, a family member, or the clinician;\n* No diagnosis of depression or affected by any form of dementia, with preserved ability in activities of daily living;\n* Objective episodic memory loss on the Wechsler Memory Scale Logical Memory II adjusted for years of schooling.\n\nIndividuals with probable Alzheimer's disease (AD):\n\n* Insidious onset with atypical course: some criteria for probable AD are met, but the onset of symptoms may have been sudden, or there is a lack of objective evidence of progressive cognitive decline;\n* Mixed etiology presentation: All criteria for probable AD are met, with concomitant cerebrovascular disorders, or the presence of features typical of another dementia or the evidence of other neurological disorders or non-neurological comorbidities;\n* A decline in performance compared to the previous level of functioning is evident, as also described by a caregiver (often a family member)\n* Onset with memory disturbances, defined as difficulty learning new information or recalling it;\n* Onset with non-mnemonic symptoms (language symptoms, particularly difficulty finding the correct words; visuospatial symptoms: perceptual deficits characterized by failure to recognize objects, people, or written words; executive symptoms: difficulties with reasoning and critical thinking);\n* MMSE score \\\u003C 23 (alternatively MoCA \\\u003C 25);\n* Objective episodic memory loss on the Wechsler Memory Scale Logical Memory II adjusted for years of schooling.\n\nExclusion criteria (Stage #1):\n\n* Individuals aged \\\u003C 65 years;\n* Individuals not residing in Italy;\n* Individuals with depression or other psychiatric disorders;\n* Individuals with forms of dementia other than Alzheimer's disease.",{"count":541,"type":23},265,"1 Year","The goal of this experimental multicentric intervention study is to validate, in Italian, the dynamic Neurocognitive Adaptation (dNA) Scale, which has already been validated in English, among a healthy elderly population (aged 65 and older) residing in Italy and patients with dementia or Alzheimer's Disease. dNA is a questionnaire designed to assess both current and past levels of engagement in physical, cognitive, creative, and social activities.\n\nThe study aims to recruit a total of 265 participants with mild cognitive impairment, subjective memory complaints, or dementia. These participants will be distributed among the 8 recruitment centers. Neuropsychological data, subjective measures, and MRI data will be collected and analyzed to address the following research questions: 1) Is there a positive correlation between scores on the dNA Scale and cognitive efficiency, as reflected in neuropsychological measures, such as episodic memory and executive functions? 2) Is there a correlation between dNA scores and improved functional connectivity within neural networks, such as the Default Network (DN)?\n\nParticipants recruited at the participating clinical centers will undergo:\n\n* A clinical interview, during which demographic and medical history information will be collected. The dNA Scale will be administered, along with a questionnaire assessing adherence to dietary habits typical of a Mediterranean diet (14-Item Mediterranean Diet Adherence Screener; MEDAS).\n* A neuropsychological assessment, aimed at evaluating general cognitive function with a particular focus on episodic memory and executive functions. The following tests will be administered: Mini-Mental State Examination (MMSE) or, alternatively, Montreal Cognitive Assessment (MoCA); Rey Auditory Verbal Learning Test (RAVLT); Trial Making Test (TMT) Form B; Digit Span Forward and Backward (WAIS or WAIS-III); and the Stroop Test.\n* Self-report questionnaires designed to assess depressive symptoms using the Geriatric Depression Scale (GDS) and anxiety symptoms using the Geriatric Anxiety Scale (GAS) (or alternatively the State-Trait Anxiety Inventory, STAI). Finally, the Cognitive Reserve Index Questionnaire will be administered to estimate Cognitive Reserve (CRIq).\n* Where available, MRI data previously acquired for clinical or diagnostic purposes will be included in the study and analyzed by the principal investigator.",[545,456,348,30,546,547,548],"Active Aging Individuals Aged 65 and Over","Dementia Alzheimer Type","Subjective Memory Complaints","Probable Alzheimer's Disease",[550,551,552,553,554,555,556,557,558,559,560,561,562],"activities","habits","lifetime protective factors","adaptation","dynamic","neurocognitive","prevention","reserve","resilience","resistance","validation","well-being","aging",{"date":406,"type":44},{"date":565,"type":23},"2026-09",{"date":567,"type":23},"2027-11-27",{"name":569,"class":80},"Neuromed IRCCS",8,{"id":572,"slug":573,"hasResults":12,"nctId":574,"briefTitle":575,"officialTitle":576,"acronym":4,"eligibilityCriteria":577,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":578,"targetDuration":4,"studyType":24,"phases":580,"briefSummary":582,"conditions":583,"keywords":588,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":594,"lastUpdatePostDateStruct":595,"startDateStruct":596,"completionDateStruct":598,"leadSponsor":600,"locationsCount":52},"100555412","early-phase-1-educational-support-group-program-for-bilingual-and-spanish-speaking-carepartners-and-people-with-progressive-aphasia-100555412","NCT06511752","Educational Support Group Program for Bilingual and Spanish-speaking Carepartners and People With Progressive Aphasia","Educational Support Group Program for Carepartners of Bilingual and Spanish-speaking Persons With Progressive Forms of Aphasia and for Persons With Progressive Forms of Aphasia","Inclusion Criteria:\n\nAll participants must:\n\n* speak Spanish and\u002For English (although participants may speak other languages in addition to Spanish and\u002For English)\n* identify as Hispanic and\u002For Latinx,\n* or their spouse\u002Ffamily member with PA identifies as Hispanic and\u002For Latinx\n* see and hear well enough to participate\n* have access to a computer or mobile device with video capability\n* have an internet connection\n\nAdditional inclusion criteria for PA\u002F language-led dementia support group participants:\n\n* Individuals with PA:\n* Has a diagnosis of PA, or language-led dementia, and aphasia is one of the primary causes of difficulty with activities of daily living\n* Aware of language difficulties and willing to discuss them\n* Able to actively engage in group discussion and complete activities with minimal support\n* Able to regularly attend meetings\n* Willing to follow the rules of the support group for interacting with others respectfully\n\nAdditional inclusion criteria for care partner support group plus implementation phase participants:\n\n* Individuals with PA:\n* Diagnosis of aphasia or dementia that is progressive in nature, and aphasia is one of the primary causes of difficulty with activities of daily living\n* Have some ability to communicate and understand communication in order to participate in training sessions\n* Are functionally able to engage in training sessions (e.g., able to maintain some attention, minimal challenging behavior that would cause disruption)\n* Have a care partner who also consents to participating in the project\n* Care partners:\n* Self-identification as a caregiver of an individual with a diagnosis of PA or language-led dementia\n* Willing to discuss caregiving for individuals with PA\u002F language-led dementia\n* Able to regularly attend meetings\n* Willing to follow the rules of the support group for interacting with others respectfully\n\nExclusion Criteria:\n\n• Beyond the inclusion criteria included above, no additional exclusion criteria apply",{"count":579,"type":23},120,[581],"EARLY_PHASE1","The current study aims to examine the benefits of an education\u002Fsupport group program for individuals with progressive aphasia (caused by various etiologies, diagnoses) and their carepartners. The current study utilizes pre-, post-treatment, and follow-up assessments to measure effects of a psychoeducational support group and an implementation\u002Fcommunication skills training phase on measures of psychosocial function, communicative effectiveness and speech\u002Flanguage function. Analysis of study-specific surveys and semi-structured interviews will provide qualitative data regarding outcomes. Before beginning the education and support group, focus groups will be run in order to set priorities for the themes to be included in the education program. Participants will join via tele-based means if preferred and these participants may reside in the United States, or internationally including Mexico and Spain.",[150,30,584,585,586,587],"Primary Progressive Aphasia","Aphasia","Progressive Aphasia","Progressive Aphasia in Alzheimer's Disease",[589,590,591,592,593],"bilingual","Spanish","Castellano","multicultural","multilingual","2026-06-08",{"date":436,"type":44},{"date":597,"type":44},"2024-05-21",{"date":599,"type":23},"2030-12",{"name":601,"class":80},"University of Texas at Austin",{"id":603,"slug":604,"hasResults":12,"nctId":605,"briefTitle":606,"officialTitle":607,"acronym":4,"eligibilityCriteria":608,"healthyVolunteers":17,"sex":18,"minAge":609,"maxAge":4,"enrollmentInfo":610,"targetDuration":4,"studyType":24,"phases":611,"briefSummary":612,"conditions":613,"keywords":623,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":594,"lastUpdatePostDateStruct":642,"startDateStruct":643,"completionDateStruct":645,"leadSponsor":647,"locationsCount":214},"100496255","cognitive-reserve-and-response-to-speech-language-intervention-in-bilingual-speakers-with-primary-progressive-aphasia-100496255","NCT05741853","Cognitive Reserve and Response to Speech-Language Intervention in Bilingual Speakers With Primary Progressive Aphasia","Cognitive Reserve and Linguistic Resilience in Bilingual Hispanics With Primary Progressive Aphasia","Inclusion Criteria:\n\n* Meets diagnostic criteria for Primary Progressive Aphasia (PPA; Gorno-Tempini et al., 2011)\n* Bilingual in Spanish and Catalan or bilingual in Spanish and English\n* Different proficiency levels across languages are expected, any prior experience in both languages is acceptable\n* Intervention study: Score of 15 or higher on the Mini-Mental State Examination\n* Note that this project will also recruit individuals to participate in assessment only, for these individuals the following inclusion criteria applies: Score of 10 or higher on the Mini-Mental State Examination\n\nExclusion Criteria:\n\n* Other central nervous system or medical diagnosis that can cause symptoms\n* Other psychiatric diagnosis that can cause symptoms\n* Significant, uncorrected visual or hearing impairment that would interfere with participation\n* Prominent initial non-speech-language impairments (cognitive, behavioral, motoric)\n* Intervention Study: Score of less than 15 on the Mini-Mental State Examination\n* Note that this project will also recruit individuals to participate in assessment only, for these individuals the following inclusion criteria applies: Score of less than 10 on the Mini-Mental State Examination","40 Years",{"count":395,"type":23},[66],"Difficulties with speech and language are the first and most notable symptoms of primary progressive aphasia (PPA). While there is evidence that demonstrates positive effects of speech-language treatment for individuals with PPA who only speak one language (monolinguals), there is a significant need for investigating the effects of treatment that is optimized for bilingual speakers with PPA. This stage 2 efficacy clinical trial seeks to establish the effects of culturally and linguistically tailored speech-language interventions administered to bilingual individuals with PPA.\n\nThe overall aim of the intervention component of this study is to establish the relationships between the bilingual experience (e.g., how often each language is used, how \"strong\" each language is) and treatment response of bilinguals with PPA. Specifically, the investigators will evaluate the benefits of tailored speech-language intervention administered in both languages to bilingual individuals with PPA (60 individuals will be recruited). The investigators will conduct an assessment before treatment, after treatment and at two follow-ups (6 and 12-months post-treatment) in both languages. When possible, a structural scan of the brain (magnetic resonance image) will be collected before treatment in order to identify if brain regions implicated in bilingualism are associated with response to treatment. In addition to the intervention described herein, 30 bilingual individuals with PPA will be recruited to complete behavioral cognitive-linguistic testing and will not receive intervention. Results will provide important knowledge about the neural mechanisms of language re-learning and will address how specific characteristics of bilingualism influence cognitive reserve and linguistic resilience in PPA.",[584,30,614,150,179,615,616,617,618,619,620,621,585,622],"Dementia, Frontotemporal","Frontotemporal Lobar Degeneration","Apraxia, Motor","Dysarthria","Communication Disorders","Language Disorders","Speech Disorders","Neurocognitive Disorders","Bilingual Aphasia",[624,625,626,584,627,628,629,630,631,632,633,634,635,636,637,638,590,591,639,640,641],"Dementia, ADRD","Bilingualism","Multilingualism","Bilingual Primary Progressive Aphasia","Cognitive Reserve","Language Decline","Bilingual Language Decline","Speech-Language Therapy","Bilingual Speech-Language Therapy","Spanish speakers","Spanish-Catalan Bilinguals","Spanish-English Bilinguals","Hispanic","Catalán","Catalan","Speech Therapy","Latino","Cognition",{"date":436,"type":44},{"date":644,"type":44},"2023-05-01",{"date":646,"type":23},"2027-11-30",{"name":648,"class":80},"Stephanie Grasso",{"id":650,"slug":651,"hasResults":12,"nctId":652,"briefTitle":653,"officialTitle":654,"acronym":4,"eligibilityCriteria":655,"healthyVolunteers":12,"sex":18,"minAge":342,"maxAge":656,"enrollmentInfo":657,"targetDuration":4,"studyType":24,"phases":658,"briefSummary":659,"conditions":660,"keywords":661,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":664,"lastUpdatePostDateStruct":665,"startDateStruct":666,"completionDateStruct":668,"leadSponsor":670,"locationsCount":672},"100596098","sunam-protocol-for-managing-bpsd-100596098","NCT07041034","SUNAM Protocol for Managing BPSD","The Effectiveness of the Systematic Unmet Needs Assessment and Management (SUNAM) Protocol on Behavioral and Psychological Symptoms of Institutionalized Residents With Dementia","Inclusion Criteria:\n\n* Diagnosed with dementia or documented as having dementia in medical records.\n* Currently residing in the long-term care facility.\n\nExclusion Criteria:\n\n* Diagnosed with schizophrenia.\n* The resident's legal representative does not provide consent for participation.","110 Years",{"count":579,"type":23},[66],"This study evaluates the effectiveness of the Systematic Unmet Needs Assessment and Management (SUNAM) Protocol, an algorithm-based intervention developed from the unmet needs theory of BPSD, in reducing Behavioral and Psychological Symptoms of Dementia (BPSD) among institutionalized residents. Both the experimental and control groups received 100 minutes of BPSD foundational education and 100 minutes of VR simulation training. The experimental group received an additional 150 minutes of SUNAM protocol training. The study aims to determine whether integrating SUNAM into caregiver training enhances BPSD assessment, management, and reduction by addressing unmet needs.",[30],[662,663],"SUNAM Protocol","Behavioral and Psychological Symptoms","2026-06-04",{"date":594,"type":44},{"date":667,"type":44},"2025-12-20",{"date":669,"type":23},"2027-03-31",{"name":671,"class":80},"Mackay Medical College",2,{"id":674,"slug":675,"hasResults":12,"nctId":676,"briefTitle":677,"officialTitle":678,"acronym":679,"eligibilityCriteria":680,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":681,"targetDuration":4,"studyType":24,"phases":683,"briefSummary":684,"conditions":685,"keywords":686,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":692,"lastUpdatePostDateStruct":693,"startDateStruct":694,"completionDateStruct":696,"leadSponsor":698,"locationsCount":52},"100563681","resilient-together-for-dementia-rt-d-100563681","NCT06619327","Resilient Together for Dementia (RT-D)","Resilient Together for Dementia: A Live Video Resiliency Dyadic Intervention for Persons With Dementia and Their Care-partners Early After Diagnosis","RT-D","Inclusion Criteria:\n\n* Recent (\\~3 month) chart documented ADRD diagnosis,\n* ADRD symptom onset after age 65\n* Cognitive assessment scores and symptoms consistent with early stage dementia, as determined by the Clinical Dementia Rating Scale scores of .5 or 1.0\n* Cognitive awareness of their problems (as determined by the treating neurologist), and ability to understand study and research protocol, as determined by a standardized teach-back method assessment\n\nAdditional inclusion criteria for dyads are:\n\n* English speaking adults (18 years or older)\n* Dyad lives together\n* At least one partner endorses clinically significant emotional distress during screening (\\>7 on Hospital Anxiety and Depression scale subscales or \\\u003C5 on the Geriatric Depression Scale)\n\nExclusion Criteria:\n\n* Patient is deemed inappropriate by the neurology team\n* Either partner has a co-occurring terminal illness\n* Patient was diagnosed with forms of dementia with clinical profiles that would preclude participation (e.g., Frontotemporal Dementia- behavioral variant), as determined by treatment team.",{"count":682,"type":23},24,[66],"This study will evaluate the feasibility and preliminary efficacy of the novel Resilient Together for Dementia (RT-D) intervention for couples following dementia diagnoses. The primary target is emotional distress, and the program aims to prevent chronic distress in at-risk couples.",[30],[30,687,688,689,690,691],"Care partners","Dyads","Emotional distress","Quality of life","Couples","2026-06-02",{"date":664,"type":44},{"date":695,"type":44},"2025-02-19",{"date":697,"type":23},"2028-07-01",{"name":699,"class":80},"Icahn School of Medicine at Mount Sinai",{"id":701,"slug":702,"hasResults":12,"nctId":703,"briefTitle":704,"officialTitle":705,"acronym":4,"eligibilityCriteria":706,"healthyVolunteers":12,"sex":18,"minAge":342,"maxAge":4,"enrollmentInfo":707,"targetDuration":4,"studyType":24,"phases":709,"briefSummary":710,"conditions":711,"keywords":717,"overallStatus":258,"whyStopped":4,"lastUpdateSubmitDate":692,"lastUpdatePostDateStruct":723,"startDateStruct":724,"completionDateStruct":726,"leadSponsor":728,"locationsCount":730},"100519351","prediction-and-prevention-of-postoperative-mortality-and-morbidity-100519351","NCT06042413","Prediction and Prevention of Postoperative Mortality and Morbidity","Real-world and Innovative Multimodal Prediction and Prevention of Postoperative Mortality and Multi-morbidities","Part I Inclusion Criteria:\n\n* 65 years of age and older\n* Identified as higher risk (≥2.5%) for 30-day mortality and MACCE based on the UPMC's Perioperative Model (EHR risk prediction algorithm)\n* Scheduled for major cardiac surgeries including coronary artery bypass and valvular repair and\u002For vascular surgeries including carotid endarterectomy, aortic aneurysm repair, and major vascular surgeries\n* RAI score ≥ 30\n* Informed consent\n* English speaking patients\n\nPart II Inclusion Criteria:\n\n* Enrolled in Aim 1 \u002F Part I Preoperative Intervention Trial\n* Scheduled for high-risk, cardiac or vascular surgery requiring intraoperative neurophysiological monitoring (IONM)\n* Moderate and high risk for mortality based on Society of Thoracic Surgery score (score \\>4)\n\nPart I Exclusion Criteria:\n\n* Children (\\\u003C18 years)\n* Patients unable to provide consent\n* Participants undergoing same day procedures or operations (discharged same day)\n* Patients with severe preoperative medical diseases such as blindness or significant visual impairment, unresolved motor weakness, or any other perioperative events or complications that would have a bearing on the patient's ability to perform study tasks, neuropsychological tests, and proposed interventions\n\nPart II Exclusion Criteria:\n\n* Pregnant women\n* Patients do not provide consent.\n* Patients are unable to participate in cognitive and other behavioral assessment due to physical limitations\n* Patients refuse any blood transfusions during surgery",{"count":708,"type":23},1200,[66],"This study will contribute to creating a prospective and automated preoperative risk assessment algorithm for predicting 30-day mortality, major adverse cardiac and cerebrovascular events (MACCE), and postoperative neurocognitive outcomes following elective cardiac and vascular surgery in older adults. It will evaluate associations between perioperative factors and longer-term neurocognitive outcomes, including postoperative neurocognitive disorder and dementia. In addition, this study will assess scalable, multimodal preoperative and intraoperative interventions to improve perioperative outcomes.\n\nThis study will explore two main hypotheses:\n\n1. Preoperative personalized prehabilitation with proactive cognitive and behavioral interventions will improve postoperative cognitive outcomes, morbidity, and mortality in high-risk elderly surgical patients.\n2. Proactive bundled intraoperative interventions are superior to reactive standard of care in reducing postoperative cognitive outcomes, MACCE, and mortality.\n\nExpected Outcome: Improved EHR algorithm will have higher predictive accuracy for MACCE and mortality while predicting postoperative cognitive outcomes.",[30,712,713,714,715,716],"Postoperative Delirium (POD)","Postoperative Neurocognitive Disorder","Major Adverse Cardiac and Cerebrovascular Events","Perioperative Complications","Postoperative Cognitive Decline",[718,719,720,721,722],"MACCE","Cognitive decline","Perioperative brain health","Neurocognitive disorder","Postoperative delirium",{"date":664,"type":44},{"date":725,"type":23},"2026-06",{"date":727,"type":23},"2027-06",{"name":729,"class":80},"University of Pittsburgh",5,{"id":732,"slug":733,"hasResults":12,"nctId":734,"briefTitle":735,"officialTitle":736,"acronym":737,"eligibilityCriteria":738,"healthyVolunteers":17,"sex":18,"minAge":298,"maxAge":4,"enrollmentInfo":739,"targetDuration":4,"studyType":24,"phases":741,"briefSummary":743,"conditions":744,"keywords":746,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":692,"lastUpdatePostDateStruct":749,"startDateStruct":750,"completionDateStruct":752,"leadSponsor":754,"locationsCount":756},"100382636","phase-4-pragmatic-evaluation-of-events-and-benefits-of-lipid-lowering-in-older-adults-100382636","NCT04262206","Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults","PRagmatic EValuation of evENTs And Benefits of Lipid-lowering in oldEr Adults (PREVENTABLE)","PREVENTABLE","Inclusion Criteria:\n\n* Community-dwelling adults\n* Age ≥75 years\n* English or Spanish as primary language\n* Able to provide a trusted contact\n\nExclusion Criteria:\n\n* Clinically evident cardiovascular disease defined as prior myocardial Infarction (MI), prior stroke, prior revascularization procedure, or a secondary prevention indication for a statin (clinician determined)\n* Hospitalization for a primary diagnosis of heart failure in the prior 12 months (Note: History of heart failure in the absence of recent hospitalization or clinically evident cardiovascular disease is not an exclusion)\n* Dementia (clinically evident or previously diagnosed)\n* Dependence in any Katz Basic Activities of Daily Living \\[ADL\\] (with the exception of urinary or bowel continence)\n* Severe hearing impairment (preventing phone follow up)\n* Unable to talk (preventing phone follow up)\n* Statin use in the past year or for longer than 5 years previously (participant reported)\n* Ineligible to take atorvastatin 40 mg (clinician determined)\n* Documented intolerance to statins\n* Active Liver Disease",{"count":740,"type":23},20000,[742],"PHASE4","PREVENTABLE is a multi-center, randomized, parallel group, placebo-controlled superiority study. Participants will be randomized 1:1 to atorvastatin 40 mg or placebo. This large study conducted in community-dwelling older adults without cardiovascular disease (CVD) or dementia will demonstrate the benefit of statins for reducing the primary composite of death, dementia, and persistent disability and secondary composites including mild cognitive impairment (MCI) and cardiovascular events.",[745,30,460],"Cognitive Impairment, Mild",[747,748],"statin","older adults",{"date":664,"type":44},{"date":751,"type":44},"2020-09-01",{"date":753,"type":23},"2026-12-31",{"name":755,"class":80},"Duke University",103,{"id":758,"slug":759,"hasResults":12,"nctId":760,"briefTitle":761,"officialTitle":762,"acronym":4,"eligibilityCriteria":763,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":764,"targetDuration":4,"studyType":24,"phases":766,"briefSummary":767,"conditions":768,"keywords":770,"overallStatus":258,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":778,"startDateStruct":780,"completionDateStruct":781,"leadSponsor":783,"locationsCount":4},"100640274","dementia-management-training-programme-for-primary-health-care-providers-100640274","NCT07617883","Dementia Management Training Programme for Primary Health Care Providers","Application and Effectiveness of a RE-AIM-Based Dementia Management Competency Training Program for Primary Health Care Providers: A Cluster Randomized Controlled Trial","Inclusion Criteria:\n\nPrimary healthcare workers aged 18 years or older\n\nRegistered healthcare professionals holding a formal license issued by the national health authority\n\nAt least 1 year of work experience\n\nAble to access the internet using a computer, tablet, or mobile phone\n\nCurrently working in a participating community health service center or township health center\n\nWilling to participate in the study and provide written informed consent\n\nExclusion Criteria:\n\nPersonnel who do not directly participate in patient disease management, including logistics or auxiliary staff\n\nInterns, trainees, or students\n\nIndividuals currently participating in other similar dementia training interventions\n\nIndividuals planning to leave their current institution within the next 12 months\n\nIndividuals who refuse to participate in the study or decline to provide written informed consent",{"count":765,"type":23},240,[66],"This study aims to evaluate the effectiveness and implementation outcomes of a dementia management competency training program for primary healthcare workers. A cluster randomized controlled trial will be conducted among primary healthcare institutions in Nanping, Fujian Province, China. Eligible primary health care providers will be recruited from community health service centers and township health centers.Participating institutions will be randomized in a 1:1 ratio to either a structured dementia management training group or a self-directed learning control group. The intervention group will receive a 12-week blended training program, including online learning, an in-person skills workshop, and case-based practice supervision. The control group will receive self-directed online learning materials. Outcomes will be assessed at baseline, immediately after the intervention, and 3 months after the intervention. The primary outcome is the change in dementia knowledge, measured using the Dementia Knowledge Assessment Scale. Secondary outcomes include dementia-related attitudes, dementia management practice competency, self-reported dementia management behaviors, objective screening and referral-related indicators, and implementation outcomes based on the RE-AIM framework.",[30,769],"Primary Health Care Providers",[353,771,772,773,774,775,776,777],"primary health care providers","dementia management","training","cluster randomized controlled trial","RE-AIM","implementation science","primary care",{"date":779,"type":44},"2026-06-03",{"date":355,"type":23},{"date":782,"type":23},"2026-12-15",{"name":784,"class":80},"Fujian Medical University"]